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TCT-511
Percutaneous Transluminal Angioplasty of the Subclavian Arteries. Long-Term
Follow up.
Isabelle P. henry1, Amira Benjelloun2, Michel C. henry3
1Polyclinique Bois Bernard, Bois Bernard, France, 2Clinique Coeur et Vaisseaux,
Rabat, Morocco, 3Cabinet de cardiologie, Nancy, France
Background: To review feasibility, safety and long-term results of subclavian artery
angioplasty.
Methods: 407 patients (males: 245, mean age: 66.1  12 y) underwent percutaneous
treatment for subclavian artery (SA) occlusive disease (stenosis: 295, occlusion: 112).
Left: 312, Right: 95, Innominate Artery: 28. Etiology: atheromatous: 397, others: 10
(Takayasu: 6) Mean % stenosis 83.4 +/- 7.8. Mean lesion length: 23.9 +/- 8.7 mm
Indications for treatment were upper limb ischemia (ULI) (n¼177) Vertebrobasilar
insufﬁciency (VBI) (n¼157), associated VBI and ULI (n¼123), coronary steal
syndrome (n¼20) asymptomatic patients with severe coronary disease (n¼73) 39
patients had associated Vertebral Artery stenosis, 81 carotid stenoses. 337 prevertebral
lesion, 45 post vertebral, both 25. Access: femoral (n¼287), brachial (n¼81), both
(n¼39). "Pull through technique": 8 cases. An isolated balloon angioplasty was per-
formed in 59 cases and 348 stents were implanted (balloon expandable: 276, self
expandable: 72).
Results: Technical success was obtained in 387 lesions (95 %) 100% for stenoses.
Only 92 occlusions were recanalized (82 %). Four periprocedural events occurred
(1.2 %), 1 major (fatal stroke), 1 T.I.A., 2 arterial thromboses. During the follow-up
(mean follow-up: 75.7 months  38.5), we had 40 restenoses (10 %). 13 occurred
following angioplasty alone (18.8 %) and 27 following angioplasty and stent
implantation (7.8 %) (P<0.01). 10 were treated by new angioplasty alone, 30 by
repeat stent implantation. Primary (PI) and secondary (PII) patencies on an intention to
treat basis at 10-year follow-up were 80.2 % and 86.5 % respectively. In patients
without initial stent placement, the rates were 67.5 % and 75.5 % while in those with
stents, the rates rose to 91.5 % and 98.2 % (P < 0.01). PI for all recanalized lesions
were 85.8 %, 79.1 % without stent, 91.8 % with stent (P < 0.04) and PII 92.8 %,
88.5 %, 98.1% respectively (P < 0.02).
Conclusions: P.T.A. is currently the treatment of choice for subclavian artery
lesions. It is a safe and effective procedure associated with low risks and good
long-term results. Stents seem to limit the restenosis rate and improve long-term
results.
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RENAL ANGIOPLASTY AND STENTING. LIMITATIONS. ROLE OF
EMBOLIC PROTECTION DEVICES
Isabelle P. Henry1, Amira Benjelloun2, Michel C. Henry3
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Background: Despite good immediate and long-term results, post procedural dete-
rioration of the renal function (RF) may occur after Renal Artery Angioplasty and
Stenting (RAAS) in 20-40 % of the patients, which limits the immediate beneﬁts of
the technique. Atheroembolism seems to play an important role. We evaluate feasi-
bility and safety of RAAS utilizing a distal protection device (DPD) to reduce the risk
of atheroembolism and avoid deteriorations of the RF.
Methods: 171 RAAS performed under DPD in 151 hypertensive patients (M:102).
Mean age: 65.2  10.8 yrs with atherosclerotic renal artery stenosis (20 bilateral). 11
pts had solitary kidneys, 62 renal insufﬁciencies. We used occlusion balloon (n ¼ 46)
or ﬁlters (n ¼ 125). We recently experimented and treated 12 patients with a new ﬁlter
the Fibernet (Lumen Biomedical Plymouth MN) which can capture particles of 40m
without compromising the ﬂow. Generated debris removed and analyzed. Blood
pressure and serum creatinine levels followed. Techniques of RAAS under protection,
limitations will be discussed.
Results: Immediate technical success: 100 %. Visible debris aspirated with Percu-
surge from all patients. Mean particle number: 98.1  60.00. Mean diameter: 201.2 
76m (38-6206). With current ﬁlters debris were removed in 80 % of the cases. With the
Fibernet visible debris were removed in all cases. Mean debris surface area: 121mm2.
Mean number of particles 28-60m : 2136  776, >60m. We observed one acute RF
deterioration. Mean follow-up: 32.2  17 months. Mean creatinine level remains
constant during follow-up. At 6 months (131 patients) 95 patients stabilized, 35 with
baseline renal insufﬁciency improved and we had only one RF deterioration (1 %) inB156 JACC Vol 62/18/Suppl B j October 27–Na patient with moderate renal insufﬁciency. At 2 years (105 patients) 73 stabilized, 28
improved and we only had 4 RF deterioration (4 %).
Conclusions: This study demonstrates the feasibility and safety of DPD during
renal interventions to protect against atheroembolism and seems to avoid RF deteri-
oration after the procedure and in the long-term. Indications will be discussed.
Improvements in DPD for renal stenting are mandatory. Randomized studies are
awaited.
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RENAL ARTERY ANEURYSMS. FIRST HUMAN TREATMENT WITH THE
MULTILAYER FLOW MODULATOR
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Background: Renal Artery Aneurysms (RAAs) can be surgically treated but due to
high risk, endovascular procedures have been proposed (coils, graft.). All
these techniques have some drawbacks, potential complications and contraindications.
We propose a new technique: the Multilayer Flow Modulator (MFM*), a self
expandable.
Methods: This MFM* is a 3D braided tube made of several interconnected
layers without any covering. Our earliest tests, in vitro (theoretical simulation
computerized Fluid dynamics, Molecular Modelization) & in vivo. demonstrate
that this MFM* reduces the velocity in the aneurismal sac up to 90% by modifying
the hemodynamic conditions.. A saccular aneurysm (A.) without collateral branch
will thrombose quickly. If a collateral branch is present the ﬂow is directed
towards this branch leading to shrinkage of the aneurysm. In fusiform A. the
ﬂow is laminated, the vortexes eliminated, eliminating the risk of rupture.
Animal experiments show excellent results. Moreover, as demonstrated in animal
and human studies this MFM preserves the collateral branches and increases the
ﬂow in them, allowing the possibility to cover any artery without compromising
the ﬂow.
Results: 8 RAAs (right:5, left: 3) in 8 pts (male: 3) mean age 58 y. treated with MFM*
6 pts had atheromatous disease, 2 a ﬁbromuscular dysplasia. One pt had a solitary
kidney. All these pts had hypertension. 10 MFM*(Ø: 5 to 6 mm, length 30 to 60 mm)
loaded in a 6 F sheath implanted by femoral approach through 8 F guiding catheter.
These stents covered major renal branches without compromising the ﬂow. Technical
success: 100%. No complications. Immediately: important reduction of the velocities
inside the aneurismal sac. 6 to 36 month follow up will be presented. All aneurysms
thrombosed with diameter reduction in some pts. The thrombosis could take several
weeks depending on the importance of collateral branches. All the side branches
remain patent.
Conclusions: The MFM* is a new technique which seems promising to treat RAAs.
Collateral branches can be covered without compromising the ﬂow and risk of renal
infarction. It is a safe procedure with a very low complications rate. Larger study is
ongoing.
TCT-514
The Multilayer Flow Modulator Stent for the Treatment of Popliteal Aneurysm.
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Background: Popliteal Artery Aneurysms (PA) are traditionally treated surgically.
Endovascular procedures with implantation of stent grafts or covered stents have been
proposed as an alternative to surgery. Results are encouraging but some problems
remain (aneurysm rupture, endoleaks, collateral branch thrombosis.). We used a new
concept of stent, the Multilayer Flow Modulator (MFM*) to treat aneurysms and try to
avoid some drawbacks encountered with endografts.
Methods: This MFM* is a 3 Dimensional braided tube made of several inter-
connected layers without any covering. Our earliest tests in vitro (theorical
simulation, computerized Fluid dynamics, Molecular Modelization) and in vivo
demonstrate that this MFM* reduces the velocity in the aneurismal sac up to 90% by
modifying the hemodynamic conditions. A saccular aneurysm without collateral
branch will thrombose quickly. If a collateral branch is present the ﬂow is direc-
ted towards this branch leading to shrinkage of the aneurysm. Animal ex-
periments show excellent results. Moreover, as demonstrated in animal and human
studies this MFM* preserves the collateral branches allowing the possibility to cover
any artery without compromising the ﬂow (renal, digestive arteries, supra aortic
vessels .).
Results: 5 PA were treated with the MFM* (male: 5, mean age: 65 y.) 9 stents (Ø6 to
8 mm, length 40 to 120 mm) were implanted by percutaneous ipsilateral femoral
approach through 8F sheath. Technical success in all patients. All aneurysm throm-
bosed. Mid-term follow up will be presented. No stent fracture. This MFM* seems
well indicated for this popliteal location.
Conclusions: A new concept of stent, the MFM* is developed to treat aneurysm. It
opens a new approach to treat peripheral aneurysms avoiding most of theovember 1, 2013 j TCT Abstracts/POSTER/Endovascular Intervention







Scomplications encountered with current endovascular techniques. The results obtained
seem promising. A larger study is ongoing.
TCT-515
THEMULTILAYER FLOWMODULATOR STENT FOR THE TREATMENT
OF THORACO ABDOMINAL AND ABDOMINAL AORTIC ANEURYSMS.
MAROCCAN EXPERIENCE
Michel C. Henry1, Amira Benjelloun2, Isabelle P. Henry3
1Cabinet de cardiologie, nancy, France, 2Clinique Coeur et Vaisseaux, Rabat,
Morocco, 3Polyclinique Bois Bernard, Bois Bernard, France
Background: Thoraco Abdominal Aortic Aneurysms (TAAA) and Abdominal Aortic
Aneurysms (AAA) are traditionally treated surgically, but more and more by inter-
ventional procedures (endografts, fenestrated, branched grafts, chimney techniques).
We used a new concept of stent, the Multilayer Stent Flow Modulator (M.F.M) to treat
these aneurysms (A) and try to avoid some major complications.
Methods: This selfexpandable M.F.M is a 3 D braided tube made of several inter-
connected layers without any covering. We will explain and demonstrate the key
principles of the stent leading to thrombosis, shrinkage of the A, eliminating the risk of
rupture. Moreover, this M.F.M preserves the collateral branches allowing the possi-
bility to cover any artery without compromising the ﬂow (renal, digestive arteries,
supra aortic vessels.).
Results: 10 TAAA, 8 AAA (7 extended to both iliac arteries) treated with MFM
in very high risk patients. 53 MFM implanted (1 to 5 per pt). o Technical success:
100% o At 30 days: no neurological complication, branch patency 100%, no death o
During the follow up we had 3 deaths not device related. CT scan control performed
at 1, 3, 6, 12, 18 months with calculation of A. Diameters and Volumes. o All
collateral branches remain patent and we observed a progressive thrombosis
and shrinkage of the aneurysmal sac depending on the size of the collaterals.
Some patients developed a thrombus after 1 month, some after 6 months and some-
even after 18 months. A signiﬁcant mean diameter reduction was observed between
baseline and 6 months: 17,25 mm reduction for the transversal diameter, 13,83 mm for
the antero posterior diameter in the TAAA group. Overtime the ratio thrombus volume
/ Total Volume is increasing and the ratio Residual Flow Volume / Total Volume is
decreasing. The problems of thrombosis, shrinkage and volume reduction of the
aneurysmal sac will be discussed. The complications rates with M.F.M appear lower
in comparison with current endovascular techniques, and with surgery.
Conclusions: The M.F.M represents an alternative to current devices to treat TAAA
and AAA. It is a safe procedure with a low complication rate. The ﬁrst results are
promising. A larger study is ongoing.
TCT-516
Argatroban and t-PA During Catheter-Directed thrombolysis for Extensive
lower Extremity Deep Venous Thrombosis
Mohsen Shariﬁ1, Wilbur K. Freeman2, Jean Chatham3, Tahereh Emami3, Curt Bay4,
Frederic Schwartz4
1Arizona Cardiovascular Consultants & A.T. Still University, Mesa, AZ, 2A.T.Still
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Background: Extensive acute deep venous thrombosis (DVT) responds favorably to
catheter directed thrombolysis (CDT). Argatroban is an effective parenteral direct
thrombin inhibitor which makes it an attractive drug for DVT treatment. There is
a paucity of data on the utilization of argatroban in combination with tPA for extensive
DVT.
Methods: 35 patients with extensive DVT involving the femoropopliteal and
iliac veins underwent PEVI. DVT was bilateral in 24 patients. A 6-8 F sheath was
placed in each popliteal vein under ultrasound guidance. DVT had developed within
10 days of major surgery in 7 patients. For maceration of the clot balloon venoplasty
was performed in all. Subsequently an infusion catheter was placed through the
popliteal sheath(s) and tPA delivered at 1mg/hr for 20-24 hours for unilateral DVT
and at 0.75 mg/hr through each infusion catheter for bilateral involvement. For
unilateral DVT, argatroban was given at 0.5 -1 mcg/kg/min through the side port of
the sheath and for bilateral DVT it was given at 0.3- 0.75 mcg/kg/min. PTT was kept
between 50-90 seconds. Every 3 hours the PTT was checked if there was a change in
the Argatroban dose. It was checked every 12 hours if the PTT had remained within
the therapeutic range. Follow-up venography was performed between 20- 30 hours
after PEVI.
Results: With the above regimen there were no bleeding complications even in the 7
patients with recent surgery. Complete or signiﬁcant resolution of thrombus was noted
in 32patients (91%). In 3 patients who previously had occlusive thrombus within their
IVC ﬁlter, the iliac and femoropopliteal DVT had resolved, however some degree of
thrombus in the IVC ﬁlter persisted. These were treated with further thrombectomy
and the procedure terminated at that time with removal of the sheaths.
Conclusions: CDT using a combination of low dose argatroban and tPA is highly
effective and safe in the treatment of massive diffuse DVT. The unacceptably high
rates of bleeding previously reported are not applicable to the contemporary era. A
synergistic effect exists between argatroban and tPA which make them an ideal
anticoagulant- thrombolytic combination for CDT.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-517
Reduction of Hospitalization and Duration of Anticoagulation for Deep Venous
Thrombosis in Patients Undergoing Percutaneous Endovenous Intervention and
Receiving Novel Anticoagulants
Mohsen Shariﬁ1, Wilbur K. Freeman2, Nikki Rezania3, Tahereh Emami4,
Jean Chatham4, Frederic Schwartz5
1Arizona Cardiovascular Consultants & A.T. Still University, Mesa, AZ, 2A.T.Still
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Background: The current recommendation for the treatment of deep venous throm-
bosis (DVT) is at least 5 days of parenteral anticoagulation with a minimum of 24
hours of overlap with a vitamin K antagonist at a therapeutic INR. It has been well
established that percutaneous endovenous intervention(PEVI) reduces the sequelae of
DVT by early removal of thrombus. The efﬁcacy and safety of novel anticoagulants
rivaroxaban and dabigatran following PEVI has not been investigated.
Methods: 93 patients with femoropopliteal , iliac , upper extremity and internal
jugular DVT who had undergone PEVI underwent initiation of dabigatran (34
patients) or rivaroxaban (59 patients) within 2 hours after their procedure. No
parenteral anticoagulation was given when oral anticoagulants were started. The mean
follow up was 183 months. Aspirin at 81mg daily was given to 18 patients who had
received an endovenous stent and was continued for 1 month. The patients were
evaluated for recurrent venous thromboembolic (VTE) disease and bleeding during
the follow- up period.
Results: There was no bleeding or recurrent VTE in any patient. Two patients could
not tolerate dabigatran due to gastrointestinal side effects. The mean duration of
parenteral treatment was 315 hours. Enoxaparin was the parenteral anticoagulant in
32 patients and unfractionated heparin in the remainder. The mean duration of
hospitalization was 295 hours. At follow-up 3 patients died due to cancer.
Conclusions: In patients undergoing PEVI, the duration of safe and effective
parenteral anticoagulation is less than the traditionally accepted minimum of 5 days.
Initiation of rivaroxaban or dabigatran soon after PEVI promotes early discharge and
obviates the inconveniences associated with regulation of INR.
TCT-518
One-Year Results of the Multi-layer Flow Modulator Stent in the Management of
Thoracoabdominal Aortic Aneurysms.
Sherif Sultan1, Niamh Hynes1
1Western Vascular Institute, Galway, Ireland
Background: We present the ﬁrst 55 cases of MFM implanted under indication for
use to treat aortic disease. All were done on compassionate basis, in 11 countries.
Primary Endpoints are Freedom from Rupture and Aneurysm-related Death.
Methods: They were 31 Crawford Thoraco-abdominal (8 Type I, 3 Type II, 9 Type
III, and 11 Type IV), 7 arch, 3 abdominal, 8 suprarenal aortic aneurysms and 6 type B
dissections. Mean age of 64.5 years +/- 18years; mean aneurysm diameter was
6.04cm+/-1.66cm (Median 5.76cm). Mean number of side branches covered was 3.7
per case (median 4, range 0-6). Total 108 stents used, mean of 1.96 MFM per
case.(Median 2, range 1-5)
Results: One-year Aneurysm-related survival was 93.7% (SE+/-4.44%). No rupture
occurred. Technical success was 98.2%. One-year all-cause survival was 84.8%
(SE+/-6.25%). There was no paraplegia. No peri-operative visceral insult. At 12
months all 202 side branches were patent. No stent fractures. One-year intervention-
free survival was 92.4% (SE+/-5.09%) At six months mean rate of sac volume
increase was 0.36% per month. At twelve months the rate of increase had slowed to
0.28% per month. The ratio of thrombus to total volume stayed almost constant over
the 12 months at 0.48, while the ratio of ﬂow to total volume fell from 0.21 to 0.12 at
12 months.
Conclusions: Increasing sac size did not herald rupture. MFM implantation instigates
a process of aortic remodeling involving initial thrombus deposition, which slowed
between six and twelve months .The MFM was not associated with loss of native side
branches.
TCT-519
Comparison of Wound Healing in Critical Limb Ischemia according to Wound
Types with and without Successful Revascularization
Norihiro Kobayashi1, Toshiya Muramatsu1, Reiko Tsukahara1, Yoshiaki Ito1,
Hiroshi Ishimori1, Keisuke Hirano1, Masatsugu Nakano1
1Saiseikai Yokohama-city Eastern Hospital, Yokohama, Japan
Background: To achieve successful revascularization is important for wound healing
in critical limb ischemia (CLI) with tissue loss following endovascular therapy (EVT).
However, we sometimes experience failure to achieve wound healing even after
successful EVT. We investigated the relationship between wound healing and
successful revascularization according to wound types.
Methods: Between April 2007 and April 2012, 171 CLI patients (204 limbs) clas-
siﬁed to Rutherford 5 or 6 were treated by EVT in our institute. In these limbs, 199
individual wounds exited on foot and were evaluated wound healing rates and time to
healing according to their wound types with and without successful revascularization.
Wound types were divided into three groups, group T (Toe wound, n¼128), group Hacts/POSTER/Endovascular Intervention B157
